To date, the first known Top1 inhibitor camptothecin (CPT) and some structurally modified CPT derivatives, such as topotecan, irinotecan, belotecan and 10-hydroxy camptothecin (Figure 1) have been applied clinically or in clinical trials for cancer treatment [7,9]. The gene discussed is TOP1; the disease is cancer.